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Programmed death 1 (PD-1) is a novel member of the CD28/
cytotoxic T-lymphocyte-associated protein-4 superfamily,
which plays an important role in the regulation of activated T
cells. However, it is not clear how PD-1 is expressed in normal
and diseased kidney, nor if it has a role in progression of
chronic renal disease. PD-1 expression and the effect of
monoclonal anti-PD-1 antibody (Ab) were examined in
murine adriamycin nephropathy (AN). BALB/c mice were
divided into three groups: (a) normal mice, (b) adriamycin
(ADR) with control immunoglobulin (Ig)G (ADR-IgG), and
(c) ADR with anti-PD-1 Ab (ADR-Ab). AN was induced by a
single intravenous injection of ADR. Anti-PD-1 Ab was given
by intraperitoneal injection on alternate days from day 0 to
day 10, or to day 18. Animals were killed at week 4. Renal
function, histological change, and cytokine expression were
examined. PD-1 mRNA was detected in kidney tissue of mice
with AN in a dose- and time-dependent manner. PD-1 was
mainly expressed on injured tubule cells and some interstitial
cells, which co-stained with a-smooth muscle actin in AN, but
not in normal kidney. Anti-PD-1 treatment up to day 18, but
not to day 10, worsened glomerular and tubulointerstitial
injury. The ratio of urinary protein/creatinine was
significantly higher in ADR-Ab mice than ADR-IgG mice.
The number of macrophages was significantly increased in
ADR-Ab mice compared with ADR-IgG mice. Blockade of
PD-1 worsened progressive renal histopathological and
functional injury in murine AN. This suggests a possible
protective role for PD-1 in chronic renal disease, and its
potential as a treatment to slow disease progression.
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A universal feature of animal and human chronic renal
disease of all types is infiltration with T cells and
macrophages into the kidney cortex.1 The effect of these
mononuclear inflammatory cells on renal injury is dependent
on their state of activation.2 Costimulatory molecules
provide the additional signals beyond interactions between
the T-cell receptor and major histocompatibility complex–-
peptide complex necessary for full T-cell activation. Blockade
or stimulation of costimulation pathways can regulate T-cell
activation, proliferation, differentiation, and cytokine secre-
tion,3 and therefore can be expected to influence the effect of
cortical inflammatory cells on renal injury.
The programmed death 1 (PD-1) receptor is a novel
member of the immunoglobulin (Ig) superfamily with 23%
homology to cytotoxic T-lymphocyte-associated protein-4 in
its IgG variable-like domain; it functions as a negative
costimulatory receptor expressed on T, B, and monocytes.4
B7H1 (PD-L1) and B7-DC (PD-L2) have been identified as
the ligands for PD-1, which are expressed on monocytes and
dendritic cells.5,6 PD-1 deficiency causes auto-antibody (Ab)-
mediated dilated cardiomyopathy in BALB/c mice and
arthritis in C57BL/6 mice.7–9 These studies indicate that
engagement of PD-1 with PD-L1 or PD-L2 contributes to
maintenance of self-tolerance. PD-1 knockout mice devel-
oped auto-Ab-mediated glomerulonephritis with predomi-
nant IgG3 deposition,7 suggesting that PD-1 also has a role in
preventing autoimmune renal disease. A single-nucleotide
polymorphism in PD-1 (PDCD1 in humans) has been
associated with increased risk of lupus, a major cause of
autoimmune nephritis, in European and Mexican patients.10
It has also been shown that resting dendritic cells induce
peripheral CD8 tolerance using PD-1 on the CD8 T cell.11
However, the effect of PD-1 in chronic renal disease,
especially in non-immune renal disease, at present is
unknown. To explore the role of PD-1 in chronic renal
disease, we examined its expression in murine adriamycin
nephropathy (AN) and the effect of its blockade with
monoclonal Ab (mAb) against PD-1.
RESULTS
Expression of PD-1 in AN
RT-PCR. PD-1 mRNA expression was increased in AN in a
dose- and time-dependent manner. The level of PD-1 mRNA
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expression was increased in parallel with the severity of
pathological renal injury in mild AN (9.5 mg/kg) vs severe
AN (9.8 mg/kg). PD-1 expression was first seen on day 7, was
moderate on day 14, and was strong on day 28 (see Figure 1).
PD-1 expression paralleled the progressive renal histologic
changes and infiltration with lymphocytes and macrophages
of murine AN.
Immunohistochemistry
Immunohistochemical staining revealed no expression of
PD-1 within the normal kidney. In mice with AN, PD-1
staining was weak at day 14 and strong by day 28, but was not
seen at day 3 and day 7 after ADR injection (control vs day 7
vs day 14 vs day 28: 070 vs 070 vs 2.673.5 vs 15.3714.1,
Po0.05 day 28 vs day 7). PD-1 was predominantly on
injured tubule cells and some interstitial cells, but not on
glomerular cells or blood vessels (Figure 2).
Dual immunofluorescence staining
To localize PD-1 expression in kidney, double immunofluor-
escent staining was used with PD-1 Ab and other Abs against
CD4þ or CD8þ T cells, macrophages, and a-smooth
muscle actin (a-SMA). PD-1 did not co-express with CD4,
CD8, or macrophages in kidney, whereas PD-1 co-expressed
with a-SMA-positive cells of dilated tubules and renal
interstitium (Figure 3).
Effect of anti-PD-1 on renal injury in AN
Histologic injury and functional impairment. All experi-
mental animals developed histological changes typical of AN,
with focal segmental glomerulosclerosis, tubular atrophy, and
interstitial damage. Overt proteinuria appeared about 5 days
after ADR administration and remained heavy throughout
the experimental period. Mean body weight fell soon after
ADR treatment and remained lower than normal controls
until being killed. The surface of AN kidneys was granular
and pale in color.
When the anti-PD-1 Ab was given until day 10, there was
no significant difference in any aspect of renal injury,
including glomerular sclerosis, tubular atrophy, and inter-
stitial change, between the ADR-Ab group and ADR-IgG
group (Table 1). Levels of urine protein and serum albumin
were similar in these two groups.
When the anti-PD-1 Ab was given until day 18, renal
cortex was more severely damaged in ADR-Ab group than
ADR-IgG group (Table 2 and Figure 4). In ADR-Ab mice,
glomerulosclerosis was significantly increased (mean7s.d. of
glomerular sclerosis index of ADR-Ab vs ADR-IgG:
0.7770.29 vs 0.4970.16, Po0.05). In ADR-Ab mice,
glomerulosclerosis was significantly increased in association
with reduction in glomerular surface area; relative interstitial
volume was expanded accompanied by a marked increase in
inflammation; and the degree of tubular atrophy as
characterized by a decrease in the height of tubular epithelial
cells, loss of brush border, and vacuolization was aggravated
in the ADR-Ab group as compared to ADR-IgG controls. The
ratio of urinary protein to creatinine was significantly higher
in ADR-Ab mice compared with ADR-IgG mice (5.771.5 vs














































Figure 1 | Dose- and time-dependent effects of ADR on PD-1
mRNA expression in murine AN. Data are mean7s.d. *Po0.05 vs
control, **Po0.01 vs 9.5 mg/kg, #Po0.05 vs day 3.
Normal











Control Day 7 Day 14 Day 28












Figure 2 | Representative immunostaining of cortical PD-1
expression in murine AN. Original magnification  200. (a) There
was no PD-1 expression in normal kidney. In AN PD-1 expression
was absent at 7 days, weak at 14 days and intense at 28 days, on
tubular cells and interstitial cells. (b) Quantification of PD-1 staining
cells showing a time-dependent increase in PD-1 staining. *Po0.05 vs
day 7.
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3.770.9 g/mmol, Po0.05). Urinary protein was increased
and serum albumin decreased in the ADR-Ab group
compared to the ADR-IgG group, but the differences did
not reach statistical significance.
Cell infiltration
In normal mice, a few macrophages and rare lymphocytes
were found within the kidney interstitium. The number of
CD4þ and CD8þ lymphocytes and macrophages was
significantly increased in the renal interstitium in AN. When
the anti-PD-1 Ab was given until day 18, but not when given
until day 10, the number of infiltrating CD4þ and CD8þ
lymphocytes was increased mildly in the ADR-Ab mice
compared to ADR-IgG mice, but this result did not reach
statistical significance (number of CD4þ cells per mm2:
21.7717.6 vs 12.5710.6; number of CD8þ cells per mm2:
9.372.1 vs 7.073.0). The ratio of CD4 to CD8 lymphocytes
was higher in Ab-treated animals (ADRþAb group:
CD4:CD8 ratio 2.772.8 vs 1.171.0 in ADRþ IgG group),
but this result was not statistically significant. In contrast,
the number of infiltrating macrophages was significantly
higher in ADR-Ab mice compared to ADR-IgG mice
(Figures 5 and 6).
Expression of monocyte chemoattractant protein-1. Reverse
transcriptase-polymerase chain reaction (RT-PCR) was used to
semiquantify monocyte chemoattractant protein-1 (MCP-1)
gene expression in renal tissue. MCP-1 mRNA expression was
higher in the ADR-Ab group compared to the ADR-IgG
group and control group (MCP-1:18S ratio, 0.4970. 36 vs
0.1470.09 vs 0.0770.06, Po0.05 comparing ADR-Ab to
ADR-IgG).
Expression of Th1 and Th2 cytokines. To investigate if the




Figure 3 | Colocalization of PD-1, a-SMA, and F4-80 (murine
macrophage marker). Representative immunofluorescence staining
of frozen sections of murine AN kidney at day 28 after ADR.
(a) Sections were labelled with anti-PD-1 Abs (green fluorescence)
and (b) a-SMA (red fluorescence). (c) Colocalization of PD-1 and
a-SMA (yellow fluorescence). (d) There was no colocalization of
PD-1 with F4/80 (green and red fluorescence).
Table 1 | Morphology and renal function in normal mice and
mice with AN, treated with anti-PD-1 mAb (ADR-Ab) or IgG







Glomerulosclerosis (0–3) 0 1.4470.78 1.2970.70
Tubular atrophy (0–3) 0 1.9470.90 1.8670.99
Interstitial infiltrates (0–3) 0 1.3170.75 0.8670.56
Urinary protein (mg/12 h) 0.2970.15 2.4970.96 2.0871.00




AN, adriamycin nephrosis; ADR-Ab, adriamycin with anti-PD-1 antibody; ADR-IgG,
ADR with control immunoglobulin G; PD-1, programmed death 1.
There was no significant difference between ADR-IgG and ADR-Ab groups.
Table 2 | Morphology and renal function in normal mice and
mice with AN, treated with anti-PD-1 mAb (ADR-Ab) or IgG







Glomerulosclerosis (0–3) 0 1.1370.90 1.8170.60*
Tubular atrophy (0–3) 0 1.1371.00 2.0070.90
Interstitial infiltrates (0–3) 0 0.6970.60 1.5070.70*
Urinary protein (mg/12 h) 0.4470.19 2.9071.96 4.5575.61




AN, adriamycin nephrosis; ADR-Ab, adriamycin with anti-PD-1 antibody; ADR-IgG,




Figure 4 | Representative morphological changes in periodic
acid-Schiff-stained sections at 28 days. Original magnification
 200. (a) Normal control, (b) ADR with IgG. (c) ADR with anti-PD-1
Ab administered for 10 days, and (d) ADR with anti-PD-1 Ab
administered for 18 days. Glomerulosclerosis, tubular atrophy, and
interstitial expansion were significantly worse in the group receiving
Ab treatment until day 18 as compared to the group receiving
Ab treatment until day 10, and the IgG control group.
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(Th)1 cytokine expression, RT-PCR was used to semiquantify
expression of Th1 and Th2 cytokines in renal tissue. There
was no significant difference in Th1 cytokine (interleukin
(IL)-2, IL-12, interferon-g) nor Th2 cytokine (IL-4, IL-10)
mRNA expression in the ADR-Ab group compared to
ADR-IgG.
Absence of detection of immune complex deposition in PD-1
Ab-treated animals. Deposition of C3, as expected, was seen
in the peritubular capillaries and tubular cells in all AN-
treated groups,12 but was not seen in glomeruli of Ab-treated
animals. There was no evidence of glomerular tuft deposition
of mouse Ig or hamster Ig. Furthermore, using enzyme-
linked immunosorbent assay, Abs against hamster Ig were
not detected in the sera of mice treated with anti-PD-1 Ab.
DISCUSSION
The present study was designed to investigate the possible
role of PD-1 in the pathogenesis of chronic renal disease.
PD-1 was significantly upregulated on tubule cells and
interstitial cells in the later stages of a robust model of focal
segmental glomerulosclerosis, murine AN. Interestingly, PD-
1 was expressed predominantly on a-SMA-positive cells in
the tubulointerstitium. Most importantly, blockade of PD-1
by a neutralizing mAb worsened the renal injury of AN.
These results indicate that PD-1 plays an important role in
protecting against renal injury in this model of chronic renal
disease.
By both RT-PCR and immunohistochemistry, we exam-
ined PD-1 expression in renal cortex in AN. The expression
of PD-1 was time- and dose-dependent, and the level of PD-1
expression correlated with severity of renal injury. These
findings suggest that PD-1 may exert its most important
effect at a later stage of renal disease rather than early after
the onset of disease. This suggestion is strengthened by the
fact that early blockade of PD-1 did not affect the severity of
renal injury.
Although PD-L1 expression has been reported on renal
tubular cells following interferon-g stimulation in vitro and
kidney transplants in vivo,13 PD-1 expression in the kidney is
largely unexplored. In the present study, we found that PD-1
was predominantly expressed on injured tubule cells as well
as on some interstitial cells. However, PD-1 was not
expressed on glomerular cells or normal tubule cells. To
determine which cells express PD-1, we characterized the
cells by double immunofluroescence staining with other cell
markers. Surprisingly, PD-1 was not expressed on T cells or
macrophages, and was only expressed on a-SMA-positive
cells, specifically injured tubule cells, and some interstitial
cells. This suggests that PD-1-expressing tubule cells are
undergoing epithelial mesenchymal transition. It is possible
that PD-1 may be a useful marker for epithelial mesenchymal
transition in tubule cells. This is in contrast to the findings by
Ding et al.14 – in normal human kidneys there was no PD-1
expression, but in renal biopsies of human type 4 lupus
nephritis, PD-1 was expressed on mononuclear cells in the
vicinity of proximal tubules.
The most important finding of this study is that
administration of anti-PD-1 mAb worsened renal injury in
AN. These results support a role for PD-1 as a negative
regulator of immune response15,16 and inhibitor of renal
injury. We did not find any deposition of C3, mouse Ig in
glomeruli of PD-1 Ab-treated animals, hence the worsening
of renal injury was unlikely to be owing to immune complex
nephritis induced by PD-1 Ab. However, administration of
anti-PD-1 mAb only during the early stage of disease did not
affect the degree of injury as compared to the IgG control
group. The reason for this may relate to the fact that PD-1
was expressed strongly on renal tubule cells and interstitial
cells only during later stages of the disease. Thus, it is
suggested that PD-1/PD-L interaction could be more
































Figure 5 | Quantitation of the number of interstitial macrophages
in normal mice, and AN mice receiving IgG or anti-PD-1 Ab for
18 days. Data are mean7s.d. *Po0.05 vs normal. **Po0.01 vs
normal, Po0.05 vs ADR-IgG.
a b
c
Figure 6 | Representative immunostaining for renal macrophages
at day 28 after ADR. Original magnification  600. (a) Normal
control, (b) ADR with IgG, and (c) ADR with anti-PD-1 Ab
administered for 18 days. The number of interstitial macrophages
was significantly increased in the group receiving Ab treatment until
day 18 compared to the IgG control group.
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As a negative regulator of T-cell responses, PD-1 has been
associated with decreased expression of pathogenic T cells
and downregulated Th1 cytokine production.17–19 As PD-1 is
weakly homologous to cytotoxic T-lymphocyte-associated
protein-4, it may possess an inhibitory function during T-cell
activation. Supporting this, experiments have shown that the
ligation of PD-1 by PD-L1 inhibited proliferation and
cytokine production by activated T cells.20–22 In addition,
PD-1 knockout mice develop a lupus-like arthritis and
glomerulonephritis. However, in the current study, there was
no difference in number of infiltrating T cells or the ratio of
CD4þ to CD8þ T cells within renal cortex between the
PD-1 blockade group and the IgG control group. Moreover,
IL-2, IL-12, and interferon-g mRNA expression within renal
cortex was not significantly increased in the PD-1 blockade
group compared to IgG controls. Therefore, mechanisms
underlying the exacerbation of renal injury by anti-PD-1 are
not related to an increase in the number of T cells nor
upregulation of Th1 cytokines. Most studies have focused on
the role of PD-1 on inhibition of T-cell activation through
PD-1 on the surface of T cells, with PDL-1 and PDL-2
expressed on antigen-presenting cells or on parenchymal cells
initiating this. Little attention has been paid to the role of
PD-1 influencing macrophages or dendritic cells through
their surface expression of PDL-1 and PDL-2 through inside-
out signalling. This has recently been shown to occur
in the cytotoxic T-lymphocyte-associated protein-4 B7
system leading to IDO production in the macrophage.
Consistent with PD-1 playing a role in downregulating
macrophages was the striking finding in this study of an
increase in the number of macrophages in the PD-1 blockade
group in comparison to IgG controls. We found that PD-1
blockade was associated with increased macrophage infiltra-
tion in treated animals. This may be owing to increased
production of chemotactic peptides as we found increased
MCP-1 expression in treated animals. Tubular cells secrete
MCP-1, so in renal disease PD-1 may inhibit tubular cell
MCP-1 production.
It is also possible that the effect of PD-1 and its blockade
in chronic renal disease may relate to an effect on regulatory
cells.23,24 Aramaki et al.25 have assessed the development of
regulatory cells in adoptive transfer experiments, and
suggested that PD-1–PDL1 interaction was essential for the
induction of regulatory cells and subsequent prolongation of
allograft survival. In recent studies on the effect of
CD4þCD25þ T cells in AN, we have demonstrated that
CD4þCD25þ T cells directly inhibit macrophage function
(unpublished observations). Therefore, interruption of PD-
1–PDL could impair regulatory T-cell function, eventually
leading to more activated macrophages in renal cortex.
In summary, the present study showed that PD-1 is
expressed on injured tubule cells, possibly those undergoing
epithelial mesenchymal transition in later stages of AN.
Blockade of PD-1 increased renal injury, suggesting that the
PD-1–PDL costimulatory pathway has a protective role in
chronic renal disease. Amplifying the inhibitory action of
PD-1 could be used as a novel therapeutic approach for
preventing progression in chronic renal disease.
MATERIALS AND METHODS
General reagents
Blocking mAb specific for murine PD-1 (clone J43, Armenian
hamster IgG) was purchased from Bioexpress Cell Culture Services
(West Lebanon, NH, USA). This Ab has been previously shown to
neutralize binding of PD-1 to its ligands PD-L1 and PD-L2.26 The
control hamster IgG was purified by protein G (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) affinity chromatography
according to the manufacturer’s instructions from the hamster
serum obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). mAbs specific for murine Abs CD4 (clone RM4-5)
and CD8 (clone 53-6.7) were purchased from BD Bioscience (San
Diego, CA, USA) and for macrophage (clone F4/80) from Serotec
(Oxford, UK). We obtained fluorescein isothiocynate (FITC)-
labelled anti-rat C3, which crossreacts with mouse C3 (MP
Biomedicals, Seven Hills, NSW, Australia), as well as FITC-labelled
goat anti-mouse Ig (Serotec, USA) and FITC-labelled goat anti-
Armenian hamster Ig (eBioscience, USA). Biotinylated rabbit anti-
rat Ig was obtained from Dako Corporation (Carpinteria, CA, USA)
and the biotin-conjugated anti-hamster Ab was obtained from
eBioscience (San Diego, CA, USA).
Animals and experimental design
BALB/c mice, weighing 20–25 g, were supplied by the Animal Care
Facility (Westmead Hospital, NSW, Australia), and bred and housed
under standard conditions.
To examine PD-1 expression, mice were divided into three
groups: normal, low dose (9.5 mg/kg) of ADR, and high dose
(9.8 mg/kg) of ADR. Mice were killed at day 3, day 7, day 14, and
day 28.
For the Ab-blocking experiment, mice were divided into the
following groups: (a) normal control; (b) ADRþ hamster IgG
(ADR-IgG), and (c) ADRþ hamster anti-PD-1 Ab (ADR-Ab).
Murine AN was induced by single tail vein injection of 9.6 mg/kg
ADR (doxorubicin hydrochloride; Pharmacia & Upjohn Pty Ltd,
Perth, Australia). All mice were housed individually. Body weight
was measured daily.
In two different Ab-blocking strategies, hamster anti-PD-1 Ab
was administrated intraperitoneally at 500 mg/dose on day 0, then at
200 mg/dose on alternate days from day 2 to day 10 or to day 18 after
ADR treatment. An equivalent amount of hamster IgG was given
according to the same protocol to the ADR-IgG groups. The dose of
Ab is similar to other studies using anti-PD-1 (clone J43) to block its
in vivo effects in experimental murine models of autoimmune type I
diabetes,26 graft-versus-host disease,27 and contact hypersensitiv-
ity.28 We used two different durations of therapy because of the
possibility of different effects on disease, as shown in experimental
autoimmune encephalitis.29
On day 28 after injection of ADR, mice were killed. Blood
samples were collected by cardiac puncture. Each kidney was
removed, weighed immediately, and divided into four pieces for
histology, immunohistology, and RNA extraction.
Renal function
Mice were placed in metabolic cages for 12 h before the killing to
collect urine for the determination of urinary protein and
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creatinine. Urinary volume was measured. Blood samples for serum
albumin were collected at the time of killing. Serum albumin, urine
creatinine, and urine protein were assayed in the Institute of Clinical
Pathology and Medical Research, Westmead Hospital. The ratio of
urine protein to creatinine was determined.
Histological assessment
Kidney slices were fixed in 10% neutral-buffered formalin
for 24 h and then dehydrated in graded alcohols and embedded
in paraffin. Tissues were cut at 5 mm and stained with periodic
acid-Schiff.
A semiquantitative score from two blinded trained observers was
used to evaluate the degree of renal injury and a minimum of eight
consecutive fields at a magnification of  400 were assessed and
scored in each section. The degree of renal injury was estimated by
evaluating the percentage of renal injury per field and was graded on
a scale of 0 to 4: 0, normal glomeruli, tubules, and interstitial
volume; 0.5, small focal area of glomerular and tubular injury and
interstitial infiltration; 1, involvement of o10% of the cortex; 2,
involvement of up to 25% of the cortex; 3, 50–75% of the cortex;
and 4, extensive damage involving 475% of the cortex.
Quantitative analysis of glomerulosclerosis was performed using
a modification of a technique described by Saito et al.30 The degree
of sclerosis was scored from 0 to 4 in each of 20 glomeruli from
periodic acid-Schiff-stained sections from each mouse. The average
of the degree of sclerosis was calculated as the index of
glomerulosclerosis. These analyses were performed with image
analysis software (ImageJ, NIH).
Immunohistochemical staining
Coronal slices of kidneys were embedded in OCT compound
(Tissue-Tek; Sakura Finetek, Torrance, CA, USA), frozen in liquid
nitrogen, and stored at 701C. Frozen sections were cut at 5 mm and
fixed with acetone at 201C for 8 min. Endogenous peroxidase
activity was blocked by incubating sections for 15 min in 0.3% (vol/
vol) H2O2 solution in phosphate-buffered saline; and endogenous
avidin-binding activity was blocked by incubating the sections with
Biotin Blocking System (Dako Corporation, Carpinteria, CA, USA);
then, nonspecific Ab binding was minimized with normal serum.
Sections were incubated with primary Abs to macrophages, CD4þ
cells and CD8þ cells for 60 min at room temperature or PD-1 Ab
overnight at 41C. After rinsing twice in phosphate-buffered saline
for 5 min each, sections were incubated with secondary Abs for
30 min at room temperature and then in avidin–biotin–horseradish
peroxidase complex for 30 min each. After phosphate-buffered
saline washing, the reaction was visualized by the addition of freshly
prepared 3, 3-diaminobenzidine tetrahydrochloride. Slides were
counterstained with hematoxylin (Sigma-Aldrich Pty Ltd, Castle
Hill, NSW, Australia), dehydrated, cover-slipped, and examined by
light microscopy. The number of macrophages, and CD4þ and
CD8þ cells was counted in eight non-overlapping cortical fields
( 400). The number of PD-1-positive cells was counted in eight
non-overlapping cortical fields ( 200). The mean number of
positive cells per field was calculated for each section.
Immunofluorescence
To exclude the possibility that worsening of AN by anti-PD-1 was
owing to immune complex nephritis, we examined for the presence
of immune complex deposition by performing immunofluorescence
for C3, mouse Ig, and hamster Ig deposition. Frozen sections of
8 mm thickness were fixed in acetone for 8 min at 201C. Back-
ground staining was blocked with avidin, biotin, and Background
Buster. Sections were incubated with FITC-labelled anti-C3 (1:40
dilution) (MP Biomedicals, USA), FITC-labelled goat anti-mouse Ig
(1:50 dilution) (Serotec, USA), or FITC-labelled goat anti-Armenian
hamster Ig (eBioscience, USA) (1:50 dilution) for 1 h and then
photographed.
To localize PD-1 expression in kidney tissue, double immuno-
fluorescence staining was used with mAbs against PD-1 and Abs
against CD4þ or CD8þ T cells, macrophage, and a-SMA on the
same sections. Frozen sections (5-mm) were fixed in acetone for
10 min at 201C and blocked with superblock solution for 30 min.
The sections were incubated with primary hamster anti-mouse mAb
against PD-1 followed by secondary FITC-conjugated anti-hamster
IgG and then incubated with the primary anti-mouse mAb against
CD4, CD8, or macrophage followed by rhodamine-conjugated
rabbit-anti-rat IgG, or incubated with primary cy3-conjugated anti-
mouse a-SMA. After mounting, the slides were examined with a
microscope equipped for fluorescence. The CD4þ , CD8þ ,
macrophage, or a-SMA-positive cells were visualized with rhoda-
mine or cy3 (red) fluorescence and the PD-1-positive cells with
FITC (green) fluorescence on the same sections.
Evaluation of Ab against hamster Ig
The presence of serum Abs against hamster Ig was determined by a
direct enzyme-linked immunosorbent assay.31 Blood was collected
from anti-PD-1-treated, IgG-treated, and normal mice at days 10,
18, and 28, and sera stored at 201C. Wells of an enzyme-linked
immunosorbent assay microtiter plate (Sarstedt, SA, Australia) were
coated with J43 Ab at a concentration of 5 mg/well in 100 ml of
coating buffer and reacted sequentially with mouse sera, alkaline
phosphatase-conjugated goat-anti-mouse polyclonal IgG (Abcam,
Cambridge, MA, USA), and substrate solution (0.5% p-nitrophenyl
phosphate (Sigma Chemical Co.) in carbonate buffer, pH 9.6).
Absorbance was read at 405 nm on an enzyme-linked immunsorbent
assay reader (Thermo Multiskan Ex). As a positive control, mouse
anti-hamster Ig (BD Pharmingen, San Diego, CA, USA) was
substituted for mouse serum.
RT-PCR
Total RNA was extracted using TRIZOL (Gibco BRL, Grand Island,
NY, USA). Frozen kidney tissue was homogenized in a volume of
0.7 ml of TRIZOL and the extracted RNA was precipitated according
to the manufacturer’s instructions and suspended in 30 ml of RNase-
free water. The yield and the purity of RNA were measured
spectrophotometrically by absorption at 260/280 nm. First-strand
cDNA was transcribed from total RNA using a Supertranscript RT-
PCR kit (Invitrogen, Branchburg, NJ, USA) with 10 mg of total RNA
in a final volume of 40 ml as per the manufacturer’s instructions. Two
units of RNase-free DNase I per microgram of RNA (Boehringer
Mannheim, Indianapolis, IN, USA) was added to the reaction
mixture, which was incubated for 20 min at 371C. cDNA then was
amplified by PCR in the presence of PCR buffer, 3 mmol/l MgCl2,
0.3 U Taq DNA polymerase, 0.2 mM deoxynucleoside triphosphates,
and 400 pmol of primers. Primers used in PCR reactions were as
follows: PD-1 forward, 50-TCAAGGCATGGTCATTGGTA-30; PD-1
reverse, 50-TAGGCCACACTAGGGACAGG-30, amplifying a 177 bp
(base pair) gene fragment; IL-2 forward, 50-AACCTGAAACTCCC
CAGGAT-30; IL-2 reverse, 50-TCCACCACAGTTGCTGACTC-30
(254 bp); MCP-1 forward, 50-GCTGGAGAGCTACAAGAGGATC
A-30; MCP-1 reverse, 50-CTCTCTCTTGAGCTTGGTGACAAA-30;
IL-10 forward, CCAGTTTTACCTGGTAGAAGTGATG-30; IL-10
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reverse, TGTCTAGGTCCTGGAGTCCAGCAGACTCAA-30; IL-4
(396 bp), IL-12 (211 bp), and interferon-g (384 bp) primer pairs
(R&D Systems, Minneapolis, MN, USA); 18s forward, 50-
GTAACCCGTTGAACCCCATT-3’; and 18s reverse, 5’-CCATC-
CAATCGGTAGTAGCG-3’ (166 bp). After an initial 4-min period
at 951C, all PCR reaction mixtures were incubated for 35 cycles at
941C for 45 s, 551C (except for IL-10, which used 601C) for 45 s,
721C for 45 s, and a final extension of 721C for 10 min 18s served as
an internal control for RNA semiquantification and standardization
of the amplified RNA products; PCR profile for 18s was 28 cycles for
30 s at 941C and 100 s at 561C followed by 5 min at 721C. PCR
products were analyzed with a 1.2% or 1.5% gel electrophoresis. The
bands were visualized with ethidium bromide, photographed, and
analyzed using image analysis software (ImageJ, NIH).
Statistical analysis
Statistical analysis was performed by one-way analysis of variance
for multiple comparisons of parametric data, and Wilcoxon’s rank-
sum test for non-parametric data. Results are expressed as the group
mean7s.d. Two group differences were analyzed by Student’s t-test
for parametric data, and Wilcoxon’s rank-sum test for non-
parametric data. A P-value of less than 0.05 was considered
statistically significant.
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